Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) and Gecko Health Innovations, Inc. said they have entered into a definitive agreement in which Teva will acquire Gecko Health Innovations.
Through the agreement, Teva will acquire CareTRxâ„¢, a novel cloud-based solution developed by Gecko Health Innovations, designed to simplify chronic respiratory disease management, connecting patients and caregivers through remote monitoring and real-time adherence tools.
Together with Gecko Health Innovations founders, Mark Maalouf and Dr. Yechiel Engelhard, Teva will explore innovative ways to apply the CareTRx technology to its robust pipeline and portfolio of respiratory products with the goal of enhancing clinical outcomes for patients.
CareTRx is a solution comprised of a hardware device which attaches to most metered-dose inhalers (MDIs) as well as a software program which synchronizes and stores data through an app-based user interface.
Gecko Health Innovations, founded in 2012 in Cambridge, MA, is a connected health company creating smart solutions that help patients better manage chronic medical conditions while bringing together real data and clinical knowledge.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world´s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area.
